FT Options’s Celgene Corp CELG Stock Holding History

FT Options’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-43,500	Closed	-$285K	–	336
2017 Q1	$285K	Buy	+43,500	New	+$5.21M	0.38%	61
2016 Q4	–	Sell	-186,300	Closed	-$201K	–	443
2016 Q3	$201K	Buy	186,300 +161,300	+645%	+$17.5M	0.16%	107
2016 Q2	$10K	Buy	+25,000	New	+$2.59M	0.01%	290
2016 Q1	–	Sell	-28,800	Closed	-$3K	–	380
2015 Q4	$3K	Buy	+28,800	New	+$3.33M	﹤0.01%	195

Other funds holding CELG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FT Options's CELG Position: Q3 2017 in Review

FT Options sold out of Celgene Corp (CELG) in Q3 2017, closing a stake of 5,000 shares — an estimated $649K sold.

FT Options first reported a position in CELG in Q4 2015 and held it in 2 quarters. The position peaked at $6.57M in Q4 2015. 1,484 funds tracked by Wall St. Rank hold CELG as of Q3 2017.

FT Options reported no remaining Celgene Corp position as of Q3 2017 after selling out during the quarter.
FT Options sold 5,000 Celgene Corp shares in Q3 2017, an estimated $649K.
FT Options first reported a position in Celgene Corp in Q4 2015 and held it in 2 quarters.
FT Options's Celgene Corp position peaked at $6.57M in Q4 2015.
1,484 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.